Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
AstraZeneca
Express Scripts
Harvard Business School
Johnson and Johnson

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Setipiprant

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Setipiprant?

Setipiprant is an investigational drug.

There have been 4 clinical trials for Setipiprant. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2011.

The most common disease conditions in clinical trials are Alopecia Areata, Alopecia, and Rhinitis, Allergic, Seasonal. The leading clinical trial sponsors are Actelion, Allergan, and [disabled in preview].

There are two US patents protecting this investigational drug and thirty international patents.

Recent Clinical Trials for Setipiprant
TitleSponsorPhase
Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in MalesAllerganPhase 2
Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic RhinitisActelionPhase 3
A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)ActelionPhase 1

See all Setipiprant clinical trials

Clinical Trial Summary for Setipiprant

Top disease conditions for Setipiprant
Top clinical trial sponsors for Setipiprant

See all Setipiprant clinical trials

US Patents for Setipiprant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Setipiprant   Start Trial Tetrahydropyridoindole derivatives Actelion Pharmaceuticals, Ltd. (Allschwil, CH)   Start Trial
Setipiprant   Start Trial Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with hermansky pudlak syndrome Brown University (Providence, RI) Yale University (New Haven, CT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Setipiprant

Drugname Country Document Number Estimated Expiration Related US Patent
Setipiprant Argentina 047928 2024-03-11   Start Trial
Setipiprant Austria 394399 2024-03-11   Start Trial
Setipiprant Australia 2005229356 2024-03-11   Start Trial
Setipiprant Brazil PI0508540 2024-03-11   Start Trial
Setipiprant Canada 2558509 2024-03-11   Start Trial
Setipiprant China 1930162 2024-03-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Medtronic
Merck
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.